Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-201-GBM in newly diagnosed glioblastoma
NCT04741984Phase 1Withdrawn
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, mRNA Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of pp65-LAMP mRNA vaccine in glioblastoma (GBM). Primary endpoints: Maximum Tolerated Dose and pp65 T-cell Immune Response. Planned start Aug 2023; status: withdrawn.
02
Drugs
pp65-LAMP mRNA vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04741984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741984.